On Thursday, Celcuity Inc. CELC announced amendments to its Phase 3 VIKTORIA-2 clinical trial evaluating gedatolisib as a ...

Celcuity (CELC) is back in focus after reporting pivotal Phase 3 VIKTORIA-1 data for gedatolisib in HR-positive, HER2-negative advanced breast cancer, expanding the VIKTORIA-2 program and preparing ...

Q1 2026 Management View CEO Brian Sullivan said, "We continue to make great progress as we prepare for the potential approval and commercial launch of gedatolisib in the third quarter," and added that ...

Thank you, Matthew, and good afternoon, everyone. Thank you for joining us to review Celcuity's first quarter 26 financial results and business update. Earlier today, Celcuity released for the first ...

(Nasdaq: CELC), a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid tumor indications, today announced updates to the Phase 3 ...

Phase 3 VIKTORIA-1 trial achieved primary endpoint with clinically meaningful improvement in progression-free survival in PIK3CA mutant cohort; ...

Celcuity plans to submit the data to the FDA as a supplemental new drug application. If everything goes to plan, the FDA will ...

Celcuity shares rose after the Phase 3 trial of a treatment for breast cancer was expanded to include endocrine-sensitive patients. Shares company rose 9.7% to $136.59 in late morning trading on ...

An analyst initiated coverage of the biotech.

View Celcuity Inc. CELC stock quote prices, financial information, real-time forecasts, and company news from CNN.